已收盘 10-07 16:00:00 美东时间
-0.002
-0.23%
Docetaxel remains the standard of care for patients with 2L/3L NSCLC without targetable alterations despite severe neutropenia (>40%) that greatly impair patients' quality of life. Six recent phase 3 studies in
09-16 19:16
CARMEL, Ind., Sept. 11, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company"), a healthcare technology company powering better health by providing meaningfu...
09-12 09:15
CARMEL, Ind., Sept. 11, 2024 /PRNewswire/ -- Merchants Bancorp (the "Company")(NASDAQ: MBIN) and its wholly owned subsidiary, Merchants Bank, have announced the appointment of Sean Sievers a...
09-12 04:05
Carisma Therapeutics (NASDAQ:CARM) announced Tuesday that its ongoing collaboration with Moderna (NASDAQ:MRNA) to develop cell therapies has been broadened to include two targets for the treatment of ...
09-10 20:01
New Code Boost IQ Exploits Data Moat to Empower US Dealers with Smarter, Faster Purchase Decisions CARMEL, Ind., Aug. 15, 2024 /PRNewswire/ -- OPENLANE, Inc. (NYSE: KAR), a leading operator ...
08-15 20:30
CARISMA Therapeutics (NASDAQ:CARM) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.32) by 15.62 percent. This is a 44.9 percent increase over losses of $(0.49) per share
08-08 20:04
Carisma Therapeutics Inc. (NASDAQ: CARM) shares are trading higher on Friday following the company's announcement of a significant development in its collaboration with Moderna.
06-29 01:59
PTGX: 11% | Protagonist Therapeutics To Join S&P SmallCap 600, Effective Prior To Opening Of Trading On July 3 DJT: 16% | Trump Media & Technology Group shares are trading higher following
06-28 20:37
5 analysts have expressed a variety of opinions on CARISMA Therapeutics (NASDAQ...
06-27 02:01
HC Wainwright & Co. analyst Mitchell Kapoor reiterates CARISMA Therapeutics (NASDAQ:CARM) with a Buy and maintains $8 price target.
06-27 00:22